A Phase 1-2, Multicenter, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.

Trial Profile

A Phase 1-2, Multicenter, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2013

At a glance

  • Drugs AEG 35156 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aegera Therapeutics
  • Most Recent Events

    • 17 Dec 2009 Planned end date changed from Mar 2009 to Nov 2009 as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 28 Aug 2008 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top